EN DE

Bait Bakfar Ltd (BKFR) Fair Value & Analysis

Healthcare · Il · Market cap 972M ILA

BB Bait Bakfar Ltd BKFR · TA
Price13.89 ILA
Fair Value9.89 ILA
Upside-28.8%
Quality52/100
Watch Bait Bakfar Ltd for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Highly profitable · 107.0% net margin
Low debt · generates free cash flow
Mixed vs. peers (7/14)
Moderate moat 60/100
Evidence: High Range 7.00 ILA – 13.74 ILA Share as image

Fair value as of: Jul 18, 2026

From 26 valuation models · updated 24 days ago

Share price −1.9% over the past month.

A solid business, but screening 29% overvalued on our models.

What matters now

  • Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (7.00 ILA to 13.74 ILA) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

20.53 ILA 7.60 ILA Fair Value 9.89 ILA Jan 2022 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.

How to read this chart

55‑month range 7.60 ILA – 20.53 ILA · fair‑value band 7.00 ILA – 13.74 ILA · the 13.89 ILA price screens above the 9.89 ILA fair value. Dashed = 300-day average. As of Jul 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bait Bakfar Ltd (BKFR) currently trades at 13.89 ILA, while our model-based Fair Value estimate is 9.89 ILA, implying the stock looks roughly 28.8% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Bait Bakfar Ltd generated revenue of 110M ILA at a net margin of 97.4%. Revenue grew 7.0% year over year. It earns a return on equity of 8.9%. Net debt stands at 86.8M ILA. Fundamentals as of Jul 18, 2026

Our scenario range runs from 7.00 ILA (bear case) to 13.74 ILA (bull case); at 13.89 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -29%, BKFR screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 7.16 ILA 10.10 ILA 13.69 ILA 80
Residual Income 14.08 ILA 14.90 ILA 16.14 ILA 76
Rev-Margin DCF 3.98 ILA 5.84 ILA 7.77 ILA 74
All 26 models by family
DCF Models
FCF DCF 7.07 ILA 10.39 ILA 14.67 ILA 38
Owner Earnings 11.96 ILA 17.25 ILA 24.05 ILA 31
5Y Revenue Exit 3.98 ILA 5.84 ILA 8.06 ILA 39
5Y EBITDA Exit 5.71 ILA 9.01 ILA 12.71 ILA 41
5Y P/E Exit 15.26 ILA 26.43 ILA 37.93 ILA 38
10Y Revenue Exit 5.11 ILA 6.98 ILA 9.21 ILA 36
10Y EBITDA Exit 6.19 ILA 8.96 ILA 12.38 ILA 37
10Y P/E Exit 11.71 ILA 19.87 ILA 29.58 ILA 35
Earnings-Based
Graham-Dodd 10.38 ILA 28.65 ILA 37.62 ILA 54
Lynch FV 5.72 ILA 8.17 ILA 10.61 ILA 50
PEG = 1.0 5.72 ILA 8.17 ILA 10.61 ILA 46
EPV 1.35 ILA 1.70 ILA 1.99 ILA 59
Dividend Discount
Gordon GGM 3.33 ILA 6.01 ILA 8.27 ILA 70
DDM Multi-Stage 3.33 ILA 4.94 ILA 6.40 ILA 61
Multiples
P/E Multiple 25.18 ILA 33.58 ILA 41.97 ILA 63
P/S Multiple 4.11 ILA 5.49 ILA 6.86 ILA 58
P/B Multiple 19.46 ILA 25.95 ILA 32.43 ILA 55
EV/EBIT 7.00 ILA 9.75 ILA 12.50 ILA 53
EV/EBITDA 5.62 ILA 7.90 ILA 10.19 ILA 54
EV/Revenue 2.05 ILA 3.46 ILA 4.87 ILA 43
Asset-Based
NCAV (Graham) 8.85 ILA 11.86 ILA 17.69 ILA 50
Growth DCF
Growth DCF 7.16 ILA 10.10 ILA 13.69 ILA 80
Rev-Margin DCF 3.98 ILA 5.84 ILA 7.77 ILA 74
Economic Profit
Residual Income 14.08 ILA 14.90 ILA 16.14 ILA 76
ROIC Compounder 1.35 ILA 1.70 ILA 1.99 ILA 72
Growth Earnings
Growth-Adj P/E 19.93 ILA 28.47 ILA 37.01 ILA 68

Widest divergence: Growth Earnings (28.47 ILA) versus Economic Profit (1.70 ILA). Highest evidence: Growth DCF (80).

Notify me when BKFR reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 110M ILA
Revenue growth (YoY) +7.0%
Net margin 97.4%
Return on equity 8.9%
Free cash flow 63.6M ILA FY2025
P/E ratio 8.6
More key figures
Operating margin 45.6%
EPS (TTM) 1.70 ILA
EPS growth (YoY) -8.3%
Net debt 86.8M ILA FY2025

Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 52/100

Of which business quality 52 · Market factors (momentum, volatility) 45

Profitability 37
Margins and returns on capital today
Quality Growth 31
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 56
Balance sheet, leverage, solvency risk
Investment 63
Disciplined investing over empire-building
Low Volatility 85
Calm price path (market factor)
Momentum 31
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 44
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Bait Bakfar Ltd manages and operates assisted living networks in Israel. The company offers health, welfare, and leisure services for the elderly population. Bait Bakfar Ltd was founded in 1988 is based in Kfar Saba, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bait Bakfar Ltd reported revenue of 110M ILA in FY2025 versus 85.4M ILA in FY2021, a compound +6.4%/yr. Reported net income was 107M ILA in FY2025, compounding +18.1%/yr from FY2021.

Growth Quality 75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
110M ILS
Latest YoY
+6.0%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.6%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.4%
Avg. growth/yr (7Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.0%
Revenue +6.4%/yr
FY21 85.4M ILA
FY22 93.0M ILA
FY23 99.1M ILA
FY24 103M ILA
FY25 110M ILA
Net income +18.1%/yr
FY21 54.9M ILA
FY22 97.0M ILA
FY23 126M ILA
FY24 133M ILA
FY25 107M ILA

BKFR screens 29% overvalued. Compare with HCA Healthcare, Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bait Bakfar Ltd · Fair Value
9.89 ILA −29%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bait Bakfar Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BKFR

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 52 · Below median
Fair Value upside −29% · Below median
Return on equity (TTM) 10% · Above median
Return on assets 1% · Below median
Net margin (TTM) 107% · Top 25%
Operating margin (TTM) 38% · Top 25%
Revenue growth 9% · Above median
Dividend yield (TTM) 0.0% · Bottom 25%
Debt / equity 0.08× · Lower than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 8.2× · Cheaper than 75% of peers
P/B 0.26× · Cheaper than 75% of peers
P/S (TTM) 2.84× · Pricier than 75% of peers
P/FCF 5.0× · Pricier than median
EV/EBITDA 8.7× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 23
FUTURE 43 · sector 24
PAST 41 · sector 30
HEALTH 96 · sector 90
DIVIDEND 1 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Bait Bakfar Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Bait Bakfar Ltd (BKFR) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of 9.89 ILA versus a price of 13.89 ILA, about −29% (overvalued).
What is the fair value of BKFR?
Our model-based fair value for Bait Bakfar Ltd is 9.89 ILA (as of Jul 18, 2026), built from audited fundamentals. The current price is 13.89 ILA.
What is the quality score of BKFR?
Bait Bakfar Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Bait Bakfar Ltd (BKFR)?
Bait Bakfar Ltd reported trailing-twelve-month revenue of about 110M ILS (latest available figure, as of Jul 18, 2026).
What is the net profit margin of BKFR?
The net profit margin of Bait Bakfar Ltd is about 97.4%, meaning it keeps roughly 97.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Bait Bakfar Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.